FLT-PET / MRI Brain Mets

Differentiating Radionecrosis From Tumour Progression Using Hybrid FLT-PET/MRI in Patients With Brain Metastases Treated With Stereotactic Radiosurgery.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04244019

Enrollment

Registered

2020-01-28

Start date

2020-10-01

Completion date

2027-03-01

Last updated

2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Metastases, Radionecrosis

Brief summary

Brain metastasis (BrM) develops in approximately 40% of cancer patients. Stereotactic radiosurgery (SRS) is a form of radiotherapy that delivers high-dose per fraction to individual lesions that is commonly used to treat BrM. Radionecrosis (RN) is an adverse event that occurs in approximately 10 - 25% of patients 6 - 24 months after treatment with SRS. Tumour progression may also occur due to local failure of treatment. Radionecrosis and tumour progression share very similar clinical features including vomiting, nausea, and focal neurologic findings. Radionecrosis and tumour progression also share overlapping imaging characteristics. Due to their similarities, physicians need to perform a surgical resection to diagnose the complication. By using a hybrid FLT-PET/MRI scan, the investigators propose that this combination scan will provide robust data with which to differentiate between radionecrosis and tumour progression without the need for surgery. The investigators plan to conduct a single center feasibility study to investigate the potential in differentiating between SRS and tumour progression in patients, including those who may have previously undergone SRS for BrM, who are suspected to have either RN or tumour progression using hybrid FLT-PET/MRI imaging.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

1. 18 years or older 2. Previously treated with SRS for BrM 3. New intracranial lesion with clinical and radiographic findings suspicious for either RN or tumour progression 4. May be planned surgical resection of the lesion in question. The determination that the lesion is appropriate for and may require surgical resection will be made by the multi-disciplinary brain metastasis team. Surgery is preferred but not required. If a patient is planned for surgery, the date does not need to be established and the patient does not need to have consented in order to be eligible for this study, however the imaging procedure will need to occur prior to the date of surgery. 5. A negative serum pregnancy test within the two-week interval immediately prior to PET-MRI imaging for women of child-bearing age 6. Ability to provide written informed concern to participate in the study

Exclusion criteria

1. Previous radiotherapy to the intended treatment volume 2. Active malignancy other than sarcoma 3. Inability to remain supine for at least 60 minutes 4. Pregnancy or breast feeding 5. Age \<18 years 6. Failure to provide written informed consent 7. Contraindication for MRI as per current institutional guidelines

Design outcomes

Primary

Measure	Time frame	Description
Radionecrosis (in patients who have previously received SRS Treatment for BrM)	24 Months	Radionecrosis will be assessed by analyzing hybrid FLT-PET/MRI images.

Secondary

Measure	Time frame	Description
Tumour Progression (in patients who have previously received SRS Treatment for BrM)	24 Months	Tumour progression will be assessed by analyzing hybrid FLT-PET/MRI images.

Countries

Canada

Outcome results